- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Onyx Pharmaceuticals Inc
+ Add to WatchlistONXX:US
95.6500 USD 0.3000 0.31%As of 20:10:00 ET on 05/17/2013.
Snapshot for Onyx Pharmaceuticals Inc (ONXX)
| Open: | 96.2600 | Day's Range: | 94.3900 - 96.4900 | Volume: | 686,966 |
|---|---|---|---|---|---|
| Previous Close: | 95.3500 | 52wk Range: | 41.2600 - 101.5690 | 1-Yr Rtn: | +128.72% |
Key Statistics for ONXX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.3907 |
| Est. EPS (USD) (12/2013) | -1.8610 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 6,957.42 |
| Shares Outstanding (M) | 72.74 |
| 30 Day Average Volume | 1,108,288 |
| Price/Book (mrq) | 5.9730 |
| Price/Sale (ttm) | 14.8361 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ONXX
Company Profile & Key Executives for ONXX
Onyx Pharmaceuticals, Inc. discovers and develops novel therapeutics based upon the genetics of human disease, with an emphasis on cancer. The Company focuses on defining the function of certain mutated genes which are known to cause cancer, and on developing therapies to reverse the effects of the mutation or to kill the cancer cell.
| N Anthony Coles JrChairman/President/CEO | Matthew K FustExec VP/CFO |
| Helen TorleyExec VP/Chief Commercial Ofcr | Suzanne M ShemaExec VP/Secy/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ONXX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page